左甲状腺素治疗患者的甲状腺激素稳态:ELSA-Brasil研究结果
基于ELSA-Brasil队列(15 105名35-74岁巴西成人,随访8.2年,2008-2019年,3个观察点),分析186例研究期间启动左甲状腺素(LT4)治疗者与243例持续LT4治疗者。启动LT4后TSH下降11%-19%、游离T4(FT4)约升高19%、游离T3(FT3)下降7%(约40%患者FT3下降>10%),并伴随甘油三酯升高及降脂药、降糖药使用增加。持续治疗者FT4稳定升高、FT3与TSH降低;47.3%(115例)至少1次FT4高于参考上限(>1.52 ng/dL),15.6%(38例)至少1次FT3低于参考下限(<0.23 ng/dL)。作者认为该结果挑战了LT4可使所有患者甲状腺激素恢复稳态的教条,需进一步研究明确其临床意义。
要点
- 启动LT4后TSH下降11%-19%、FT4约升高19%、FT3下降7%,约40%患者FT3下降>10%。
- 持续LT4治疗者47.3%(115例)至少1次FT4>1.52 ng/dL,15.6%(38例)至少1次FT3<0.23 ng/dL。
- 尽管TSH正常,相当部分LT4治疗者FT4、FT3反复超出参考范围。
核心结论
- 作者认为结果挑战了LT4治疗可使所有甲状腺功能减退患者恢复甲状腺激素稳态的教条,需进一步研究明确这些发现的临床意义。
研究设计与样本
- ELSA-Brasil纵向研究随访15 105名35-74岁巴西成人8.2年(2008-2019年),设3个观察点检测TSH、FT4、FT3等指标。
- 分析186例研究期间启动LT4治疗者与243例持续LT4治疗者。
主要发现
- 启动LT4治疗使TSH下降11%-19%、FT4约升高19%、FT3下降7%,约40%的LT4治疗者FT3下降>10%。
- 上述变化伴随甘油三酯水平升高及降脂药和降糖药使用增加。
- 持续LT4治疗者表现为FT4稳定升高、FT3与TSH降低。
- 115例(47.3%)至少1次FT4高于对照参考范围(>1.52 ng/dL),38例(15.6%)至少1次FT3低于参考范围(<0.23 ng/dL)。
关键数值与推荐
- FT4高于对照参考范围定义为>1.52 ng/dL,FT3低于参考范围定义为<0.23 ng/dL。
- 启动LT4后TSH下降11%-19%、FT4约升高19%、FT3下降7%,约40%患者FT3下降>10%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究明确这些发现的临床意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The effectiveness of levothyroxine (LT4) in restoring thyroid hormone (TH) homeostasis, particularly serum thyroxine (T4) and triiodothyronine (T3) levels, remains debatable. OBJECTIVE: This work aimed to assess TH homeostasis in LT4-treated individuals using data from the Longitudinal Study of Adult Health in Brazil (ELSA-Brasil) study. METHODS: The ELSA-Brasil study follows 15 105 adult Brazilians (aged 35-74 years) over 8.2 years (2008-2019) with 3 observation points assessing health parameters including serum thyrotropin (TSH), free T4 (FT4), and free T3 (FT3) levels. We analyzed 186 participants that initiated treatment with LT4 during the study, and 243 individuals continuously treated with LT4 therapy. RESULTS: Initiation of therapy with LT4 resulted in an 11% to 19% decrease in TSH, an approximately 19% increase in FT4, and a 7% reduction in FT3 serum levels (FT3 dropped >10% in ∼40% of the LT4-treated patients). This was associated with an increase in triglyceride levels and utilization of hypolipidemic and antidiabetic medications. Participants continuously treated with LT4 exhibited a stable elevation in serum FT4 and a reduction in serum FT3 and TSH levels. While 115 participants (47.3%) had at least 1 serum FT4 levels above the control reference range (>1.52 ng/dL), 38 participants (15.6%) had at least 1 serum FT3 below the reference range (<0.23 ng/dL). CONCLUSION: The present results challenge the dogma that treatment with LT4 for hypothyroidism restores TH homeostasis in all patients. A substantial number of LT4-treated patients exhibit repeated FT4 and FT3 levels outside the normal reference range, despite normal TSH levels. Further studies are needed to define the clinical implications of these findings.
引用
- Penna GC, Bensenor IM, Bianco AC, et al. Thyroid Hormone Homeostasis in Levothyroxine-treated Patients: Findings From ELSA-Brasil. J Clin Endocrinol Metab. 2024. PMID: 38506164. doi:10.1210/clinem/dgae139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。